As India struggles with vaccine shortages and a laggard inoculation programme, a clutch of local manufacturers, including Hetero Group of Companies, Gland Pharma and Stelis Biopharma has set out to produce the contentious Sputnik V vaccine in a bid to alleviate supply constraints. Subscribe to Forbes India for early access
Interior View of Hetero Biopharma manufacturing facility, Jadcherla, Hyderabad, India.
Vamsi Krishna Bandi believes that the Russian Sputnik-V vaccine has the potential to be a game-changer in India’s inoculation programme.
(This story appears in the 04 June, 2021 issue of Forbes India. To visit our Archives, click here.)